Phathom Pharmaceuticals I... (PHAT)
| Bid | 4.6 |
| Market Cap | 330.78M |
| Revenue (ttm) | 55.25M |
| Net Income (ttm) | -334.33M |
| EPS (ttm) | -5.29 |
| PE Ratio (ttm) | -0.9 |
| Forward PE | -1.75 |
| Analyst | Buy |
| Ask | 5.01 |
| Volume | 426,272 |
| Avg. Volume (20D) | 1,215,340 |
| Open | 4.60 |
| Previous Close | 4.63 |
| Day's Range | 4.54 - 5.07 |
| 52-Week Range | 3.81 - 19.71 |
| Beta | 0.35 |
About PHAT
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal re...
Analyst Forecast
According to 5 analyst ratings, the average rating for PHAT stock is "Buy." The 12-month stock price forecast is $26, which is an increase of 447.37% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
Phathom Pharmaceuticals, Inc. (PHAT) Q4 2024 Earnings Call TranscriptPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants Eric Sciorilli - Head, Investor Relations Terrie Curran - President & Chief ...
